Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Europe Hemoglobinopathies Market Outlook

The global hemoglobinopathies market size was valued at USD 6.9 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of thalassemia and sickle cell anemia. The global market is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to attain USD 15.9 billion by 2032.

Key Takeaways

  • Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The increasing prevalence of hemoglobinopathies in European countries is poised to directly impact the market demand for effective and affordable treatment solutions in coming years.
  • One of the major Europe hemoglobinopathies market trends is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023, the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals (Ireland) Limited to treat transfusion‑dependent beta thalassemia and severe sickle cell disease.
  • The market is witnessing a rise in strategic partnerships among the key market players to expand their presence in the European market. In March 2023, AddMedica and Abacus Medicine Pharma Services entered a partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) in the Western Europe region.

Europe Hemoglobinopathies Market Analysis

Hemoglobinopathies are a group of inherited blood disorders that affect the structure, function, or production of the hemoglobin molecule. The condition is usually resulted due to genetic mutations that damage or deform the red blood cells. Sickle cell anemia and thalassemia are considered the most common types of hemoglobinopathies. The disorder presents a significant health challenge in Europe. Several factors such as technological advancements in screening and diagnostic tools, rigorous research, and development efforts, and rising regulatory support are expected to drive the Europe hemoglobinopathies market growth.

The increasing prevalence of hemoglobinopathies in Europe is poised to directly impact the market demand for effective and affordable treatment solutions. Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The rising cases of the disease stimulate innovation in screening, diagnosis, and management strategies. Moreover, the heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies is likely to bolster Europe hemoglobinopathies market demand in the forecast period.

The favorable regulatory environment in the region is expected to improve access to innovative therapies for the growing patient base as well as encourage investments from the key market players. In December 2023, the European Medicines Agency (EMA) granted approval to the first gene therapy Casgevy (exagamglogene autotemcel) developed by Ireland based Vertex Pharmaceuticals Limited to treat transfusion‑dependent beta thalassemia and severe sickle cell disease in patients aged 12 or older. The medication employs CRISPR/Cas9 gene editing technology and has the potential to reduce the burden of frequent transfusions, thereby improving the patient’s quality of life and elevating Europe hemoglobinopathies market value.

A major market trend is the rise in strategic partnerships among the key market players to share expertise and resources and subsequently expand their presence in the European market. In March 2023, AddMedica (Specialty Pharma Company in France) and Abacus Medicine Pharma Services (a pharmaceutical company in England) entered a strategic partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) for patients aged 2 years and above. It is to be applied in three countries of western Europe, including Belgium, the Netherlands, and Luxembourg. Siklos has the potential to prevent red blood cells from taking a sickle-celled shape and reduce the risk of vaso-occlusive crises (VOCs) in the affected people. The increased emphasis on marketing and distribution of sickle cell therapies to ensure the accessibility of treatment options in the region is anticipated to augment the market share in the forecast period.

Europe Hemoglobinopathies Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup Categories
Type Thalassemia, Sickle Cell Disease, Other Hb Variants Diseases
Treatment Stem-Cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, Ace Inhibitors, Hydroxyurea, Monoclonal Antibody Medication, Others
Test Type Routine Red Blood Cell (RBC) Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin Solubility Test
End User Hospitals and Clinics, Diagnostics Laboratories, Others
Country United Kingdom, Germany, France, Italy

Europe Hemoglobinopathies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Limited
  • Merck KGaA
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Neusoft Corporation
  • Emmaus UK
  • Biogen

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Treatment
  • Test Type
  • End User
  • Region
Breakup by Type
  • Thalassemia
  • Sickle Cell Disease
  • Other Hb Variants Diseases
Breakup by Treatment
  • Stem-Cell Transplantation
  • Blood Transfusions
  • Analgesics
  • Antibiotics
  • Ace Inhibitors
  • Hydroxyurea
  • Monoclonal Antibody Medication
  • Others
Breakup by Test Type
  • Routine Red Blood Cell (RBC) Count
  • Genetic Testing
  • Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
  • Hemoglobin Isoelectric Focusing (Hb IEF)
  • Hemoglobin electrophoresis (Hb ELP)
  • Hemoglobin Solubility Test
Breakup by End User
  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others
Breakup by Region
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Limited
  • Merck KGaA
  • Alnylam Pharmaceuticals, Inc.
  • Sanofi 
  • Neusoft Corporation
  • Emmaus UK
  • Biogen

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The Europe hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032. 

The heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies are fuelling the demand for the market.

One of the significant trends in the market is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023, the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals Limited to treat transfusion dependent beta thalassemia and severe sickle cell disease.

Based on the type, the market is segmented into thalassemia, sickle cell disease, and other Hb variants diseases.

Treatments available in the market include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, and monoclonal antibody medication, among others.

By test type, the market is divided into Routine Red Blood Cell (RBC) Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), and Hemoglobin Solubility Test.

End users of the market are hospitals and clinics, diagnostics laboratories, among others.

The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.

The key players in the market are Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Limited, Merck KGaA, Alnylam Pharmaceuticals, Inc., Sanofi, Neusoft Corporation, Emmaus UK, and Biogen.

Purchase Full Report

Datasheet

 

USD 2,639

USD 2,299

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 4,399

USD 3,699

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 5,829

USD 4,899

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 6,929

USD 5,899

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124